Editas Stock Analysis


USD 12.24  0.08  0.66%   

Editas Medicine price drop over the last few months could raise concerns from private investors as the firm is trading at a share price of 12.24 on 1,464,400 in volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in September. However, diversifying your holdings with Editas Medicine or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.31. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Editas Medicine partners.
Continue to Investing Opportunities.
The Editas Medicine stock analysis report makes it easy to digest most publicly released information about Editas Medicine and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Editas Stock analysis module also helps to analyze the Editas Medicine price relationship with some important fundamental indicators such as market cap and management efficiency.

Editas Stock Analysis Notes

About 71.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Editas Medicine recorded a loss per share of 2.73. The entity had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Katrine Bosley at 617 401 9000 or check out https://www.editasmedicine.com.

Editas Medicine Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Editas Medicine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Editas Medicine or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Editas Medicine generated a negative expected return over the last 90 days
Editas Medicine has high historical volatility and very poor performance
The company reported the previous year's revenue of 31.8 M. Net Loss for the year was (184.49 M) with loss before overhead, payroll, taxes, and interest of (116.96 M).
Editas Medicine currently holds about 452.56 M in cash with (162.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59.
Roughly 71.0% of the company shares are held by institutions such as insurance companies
Latest headline from seekingalpha.com: Intellia falls as analysts react to CRISPR readouts - Seeking Alpha

Editas Medicine Upcoming and Recent Events

Earnings reports are used by Editas Medicine to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Editas Medicine previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Editas Medicine SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Editas Medicine prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Editas Medicine investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Editas Medicine specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
11th of July 2022
Unclassified Corporate Event
13th of June 2022
Submission of Matters to a Vote of Security Holders
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of April 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
9th of March 2022
Unclassified Corporate Event
24th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of February 2022
Unclassified Corporate Event

Editas Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Editas Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Editas Medicine backward and forwards among themselves. Editas Medicine's institutional investor refers to the entity that pools money to purchase Editas Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
State Street CorpCommon Shares7.9 M93.2 M
Blackrock IncCommon Shares6.7 M79.5 M
Vanguard Group IncCommon Shares6.6 M78.5 M
Citadel Advisors LlcCommon Shares1.3 M14.9 M
Geode Capital Management LlcCommon Shares1.2 M14.5 M
Jpmorgan Chase CoCommon Shares1.2 M14.2 M
Capital World InvestorsCommon Shares1.1 M13 M
Note, although Editas Medicine's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Editas Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 839.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Editas Medicine's market, we take the total number of its shares issued and multiply it by Editas Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (17.38) % which means that it has lost $17.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (34.2) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine management efficiency ratios could be used to measure how well editas medicine manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of October, Editas Medicine shows the Coefficient Of Variation of 3648.39, mean deviation of 4.3, and Downside Deviation of 5.03. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Editas Medicine, which can be compared to its rivals. Please confirm Editas Medicine information ratio, as well as the relationship between the potential upside and kurtosis to decide if Editas Medicine is priced favorably, providing market reflects its regular price of 12.24 per share. Given that Editas Medicine has jensen alpha of 0.4172, we urge you to verify Editas Medicine's prevailing market performance to make sure the company can sustain itself at a future point.

Editas Medicine Price Movement Analysis

The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from Editas Medicine price series.

Editas Medicine Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Editas Medicine Predictive Daily Indicators

Editas Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Editas Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Editas Medicine Forecast Models

Editas Medicine time-series forecasting models is one of many Editas Medicine's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Editas Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Editas Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Editas Medicine prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Editas shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Editas Medicine. By using and applying Editas Stock analysis, traders can create a robust methodology for identifying Editas entry and exit points for their positions.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people.

Current Editas Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Editas analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Editas analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Editas Medicine current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Editas analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Editas stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Editas Medicine, talking to its executives and customers, or listening to Editas conference calls.
Editas Analyst Advice Details

Editas Stock Analysis Indicators

Editas Medicine stock analysis indicators help investors evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock analysis, traders can identify Editas Medicine position entry and exit signals to maximize returns.
Quick Ratio12.44
Fifty Two Week Low9.59
Revenue Growth1,578.60%
Average Daily Volume Last 10 Day1.96M
Shares Short Prior Month16.77M
Average Daily Volume In Three Month1.67M
Shares Percent Shares Out24.26%
Forward Price Earnings-3.52
Short Percent Of Float27.22%
Float Shares68.46M
Fifty Two Week High59.43
Fifty Day Average16.07
Enterprise Value To Ebitda-2.45
Two Hundred Day Average17.06
Enterprise Value To Revenue13.89
Continue to Investing Opportunities. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for analysis

When running Editas Medicine price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine Editas Medicine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.